RESUMO
Chronic viral hepatitis is a systemic disease characterized by a wide range of extrahepatic manifestations, such as cognitive impairment, chronic fatigue, sleep disorders, depression, anxiety and a decrease in quality of life. This article presents a summary of the main theories and hypotheses about the occurrence of cognitive impairment, features of treatment of patients with chronic viral hepatitis. Often, extrahepatic manifestations can outstrip the clinical manifestations of liver damage itself, which requires the use of additional diagnostic and treatment methods, and they can also significantly change the treatment tactics and prognosis of the disease. Changes in neuropsychological parameters and cognitive impairments are often recorded in patients with chronic viral hepatitis at stages characterized by the absence of significant liver fibrosis and liver cirrhosis. These changes usually occur regardless of the genotype of the infection and in the absence of structural damage to the brain. The purpose of this review is to study the main aspects of the formation of cognitive impairment in patients with chronic hepatitis, cirrhosis of viral etiology.
Assuntos
Viroses do Sistema Nervoso Central , Hepatite Viral Humana , Humanos , Qualidade de Vida/psicologia , Cirrose Hepática/etiologia , Cirrose Hepática/diagnóstico , Cirrose Hepática/psicologia , Encéfalo , Hepatite Crônica , Hepatite Viral Humana/complicações , Hepatite Viral Humana/diagnósticoRESUMO
We performed a systematic review and meta-analysis on the effectiveness of ribavirin use for the prevention of infection and death of healthcare workers exposed to patients with Crimean-Congo hemorrhagic fever virus (CCHFV) infection. Splashes with blood or bodily fluids (odds ratio [OR] 4.2), being a nurse or physician (OR 2.1), and treating patients who died from CCHFV infection (OR 3.8) were associated with healthcare workers acquiring CCHFV infection; 7% of the workers who received postexposure prophylaxis (PEP) with ribavirin and 89% of those who did not became infected. PEP with ribavirin reduced the odds of infection (OR 0.01, 95% CI 0-0.03), and ribavirin use <48 hours after symptom onset reduced the odds of death (OR 0.03, 95% CI 0-0.58). The odds of death increased 2.4-fold every day without ribavirin treatment. Ribavirin should be recommended as PEP and early treatment for workers at medium-to-high risk for CCHFV infection.
Assuntos
Pessoal de Saúde , Vírus da Febre Hemorrágica da Crimeia-Congo/isolamento & purificação , Febre Hemorrágica da Crimeia/epidemiologia , Profilaxia Pós-Exposição , Antivirais/administração & dosagem , Antivirais/uso terapêutico , Saúde Global , Febre Hemorrágica da Crimeia/tratamento farmacológico , Febre Hemorrágica da Crimeia/mortalidade , Humanos , Ribavirina/administração & dosagem , Ribavirina/uso terapêuticoRESUMO
Purpose: To determine the level of seroprevalence to the virus of Crimean-Congo Hemorrhagic Fever (CCHF) in population of rural area of the particular districts of Turkestan region, Kazakhstan and its connection with epidemiological alerts. Materials and methods: For determining the real Crimean-Congo hemorrhagic fever virus (CCHFV) circulation in Turkestan region, Kazakhstan, massive sero-epidemiologic studies were conducted. Healthy residents of Turkestan Region aged from 10 to 75 years were examined without having been previously registered with CCHF. After receiving an informed consent, 5 ml of venous blood was collected for ELISA assay using the following test kits: VectoCrimea-CHF-IgG and VectoCrimea-CHF-IgM by the Vector-Best JSC. Findings on CCHF morbidity rate along with prevalence of ticks were received from the reports of the Committee of Sanitary and Epidemiological Control of the Ministry of Healthcare of the Republic of Kazakhstan. Results: Blood serum samples were collected prospectively from 4259 residents in all 16 districts of rural areas of Turkestan region. CCHF seroprevalence was detected in 2.39% of cases. Anamnesis of a tick-bite along with livestock contact in 18-30 years and 41-50 years age groups were considered as risk factors. The highest rate of CCHF seroprevalence was determined in the following recognized endemic regions and districts, namely Sozak District (4.04%), Turkestan Region (3.85%), Jetisu Region (3.6%). Reactivity probes were detected in residents of all 16 districts of Turkestan Region. The research statistics displayed that CHHF pathogen considerably increased its circulation in the endemic regions and the disease communicated into a number of new districts. Conclusion: IgG ELISA was performed to screen CCH-FV in 4259 village inhabitants of Turkestan Region and revealed the presence of antibodies in 2.39% of its population. Weak linear correlation relationship was established between CCHFV seroprevalence rate and CCH-FV morbidity rate in the particular districts of Turkestan Region. As people grow older, CCHFV IgG detection rate increases. Living on CHHF endemic territories is a serious risk factor to become CHHF positive which is characterized by manifestation of the subclinical forms of this disease.
RESUMO
Background: At the beginning of the Coronavirus disease 2019 (COVID-19) pandemic, studies showed that the risk of severe disease was higher in pregnant women. Objective: This study investigates the characteristics of severe and critical types of COVID-19 coronavirus infection in pregnant women. Materials and Methods: This prospective cross-sectional study compared the medical records of 120 pregnant women with severe and very severe COVID-19 treated at the Infectious Disease Center, Shymkent, Kazakhstan from December 2021 to May 2022. Factors such as time of hospital admission, hospitalization period, maternal comorbidities, age, pregnancy and postpartum complications, pregnancy outcomes, and treatment type were analyzed. Results: 87 (72.5%) pregnant women with severe and 33 (27.5%) with critical type of COVID-19 were included. The following data were obtained when comparing the pregnancy parity of the subjects, depending on the gestational age: in 1-12 wk, the indicator was 3.75 ± 0.95; in 13-27 wk 3.00 (Q1-Q3: 2.00-4.00), in 28-40 wk 3.00 (Q1-Q3: 2.00-4.00). Severe COVID-19 coronavirus infection occurs in women with more than a third pregnancy (Me 3.00 [Q1-Q3: 2.00-4.00]). Conclusion: There is a risk of disease progression to severe and critical COVID-19 in pregnant women older than 33 yr of age and at 28-40 wk gestation. Early referral to a doctor in hospital, timely hospitalization, and initiated treatment reduces the risk of aggravation of the patient's condition and development of formidable complications.
RESUMO
Crimean-Congo hemorrhagic fever (CCHF), caused by Crimean-Congo hemorrhagic fever virus (CCHFV), is endemic in Africa, Asia, and Europe, but CCHF epidemiology and epizootiology is only rudimentarily defined for most regions. Here we summarize what is known about CCHF in Central, Eastern, and South-eastern Asia. Searching multiple international and country-specific databases using a One Health approach, we defined disease risk and burden through identification of CCHF cases, anti-CCHFV antibody prevalence, and CCHFV isolation from vector ticks. We identified 2313 CCHF cases that occurred in 1944-2021 in the three examined regions. Central Asian countries reported the majority of cases (2,026). In Eastern Asia, China was the only country that reported CCHF cases (287). In South-eastern Asia, no cases were reported. Next, we leveraged our previously established classification scheme to assign countries to five CCHF evidence levels. Six countries (China, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan) were assigned to level 1 or level 2 based on CCHF case reports and the maturity of the countries' surveillance systems. Two countries (Mongolia and Myanmar) were assigned to level 3 due to evidence of CCHFV circulation in the absence of reported CCHF cases. Thirteen countries in Eastern and South-eastern Asia were categorized in levels 4 and 5 based on prevalence of CCHFV vector ticks. Collectively, this paper describes the past and present status of CCHF reporting to inform international and local public-health agencies to strengthen or establish CCHFV surveillance systems and address shortcomings.
Assuntos
Vírus da Febre Hemorrágica da Crimeia-Congo , Febre Hemorrágica da Crimeia , Carrapatos , Animais , Humanos , Febre Hemorrágica da Crimeia/epidemiologia , Ásia , Ásia OrientalRESUMO
BACKGROUND: Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in >95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries. METHODS: A survey including 20-item questionnaire was sent to experts in viral hepatitis. Countries were evaluated according to their income categories by the World Bank stratification. RESULTS: Experts from 26 countries responded to the survey. As of May 2016, HCV prevalence was reported as low (≤1%) in Croatia, Czech Republic, Denmark, France, Germany, Hungary, the Netherlands, Portugal, Slovenia, Spain, Sweden, UK; intermediate (1-4%) in Azerbaijan, Bosnia and Herzegovina, Italy, Kosovo, Greece, Kazakhstan, Romania, Russia, Serbia and high in Georgia (6.7%). All countries had national guidelines except Albania, Kosovo, Serbia, Tunisia, and UK. Transient elastography was available in all countries, but reimbursed in 61%. HCV-RNA was reimbursed in 81%. PegIFN/RBV was reimbursed in 54% of the countries. No DAAs were available in four countries: Kazakhstan, Kosovo, Serbia, and Tunisia. In others, at least one DAA combination with either PegIFN/RBV or another DAA was available. In Germany and the Netherlands all DAAs were reimbursed without restrictions: Sofosbuvir and sofosbuvir/ledipasvir were free of charge in Georgia. CONCLUSION: Prevalence of HCV is relatively higher in lower-middle and upper-middle income countries. DAAs are not available or reimbursed in many Eurasia and European countries. Effective screening and access to care are essential for reducing liver-related morbidity and mortality.
Assuntos
Hepacivirus , Hepatite C/diagnóstico , Hepatite C/tratamento farmacológico , Antivirais/uso terapêutico , Ásia/epidemiologia , Técnicas de Imagem por Elasticidade , Europa (Continente)/epidemiologia , Feminino , Hepatite C/epidemiologia , Hepatite C/virologia , Humanos , Reembolso de Seguro de Saúde , Masculino , Prevalência , Carga ViralRESUMO
BACKGROUND: Crimean-Congo hemorrhagic fever (CCHF) is acute viral infection and a major emerging infectious diseases threat, affecting a large geographical area. There is no proven antiviral therapy and it has a case fatality rate of 4-30%. The natural history of disease and outcomes of CCHF in pregnant women is poorly understood. OBJECTIVES: To systematically review the characteristics of CCHF in pregnancy, and report a case series of 8 CCHF cases in pregnant women from Russia, Kazakhstan and Turkey. METHODS: A systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement protocol. PubMed, SCOPUS, Science Citation Index (SCI) were searched for reports published between January 1960 and June 2016. Two independent reviewers selected and reviewed studies and extracted data. RESULTS: Thirty-four cases of CCHF in pregnancy were identified, and combined with the case series data, 42 cases were analyzed. The majority of cases originated in Turkey (14), Iran (10) and Russia (6). There was a maternal mortality of 14/41(34%) and fetal/neonatal mortality of in 24/41 cases (58.5%). Hemorrhage was associated with maternal (p=0.009) and fetal/neonatal death (p<0.0001). There was nosocomial transmission to 38 cases from 6/37 index pregnant cases. CONCLUSION: Cases of CCHF in pregnancy are rare, but associated with high rates of maternal and fetal mortality, and nosocomial transmission.